Orosomucoid as the accelerator of hepatic fibrosis.

T, Ozeki; M, Kan; K, Iwaki; K, Ohuchi

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 1987

Data sources: Europe PubMed Central

Orosomucoid as the accelerator of hepatic fibrosis.

descriptionPublicationkeyboard_double_arrow_right Article 02 Feb 1987 English Journal:British journal of experimental pathology, volume 67 (issn: 0007-1021,

Copyright policy )

Authors: T, Ozeki; M, Kan; K, Iwaki; K, Ohuchi;

pmid: 3790431

pmc: PMC2012968

Orosomucoid as the accelerator of hepatic fibrosis.

- Summary
- Subjects
- Metrics

Abstract

The administration of orosomucoid to rats with chronic liver injury accelerated hepatic fibrosis. An increase of hepatic fibres was seen histologically and the content of hydroxyproline in the liver collagen fraction increased. Moreover, the incorporation of 3H-proline into the collagen fraction of injured liver was increased by the administration of orosomucoid.

Keywords

Male, Liver Diseases, Rats, Inbred Strains, Orosomucoid, Fibrosis, Rats, Hydroxyproline, Liver, Animals, Collagen

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	5
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average